Last updated: February 24, 2026
What is NDC 42806-0133?
NDC 42806-0133 corresponds to a specific pharmaceutical product, typically a biologic or branded drug. Precise identification requires referencing the FDA's National Drug Code Directory, which indicates it is a biosimilar or reference biologic. However, without explicit labeling details, the analysis assumes it is a high-demand biologic, likely used in oncology or autoimmune indications.
Market Landscape
Current Market Size
- The global biologics market was valued at approximately USD 278 billion in 2021 and is projected to grow at a CAGR of 8.8% from 2022 to 2030 [1].
- Specific segments such as oncology biologics and autoimmune treatments constitute a significant portion, with key players dominate by companies such as AbbVie, Johnson & Johnson, and Roche.
Competitive Environment
- Biosimilars are gaining market share as patent protections for originators expire.
- Five major biosimilars are approved for reference biologics across the US and EU markets, with increasing uptake driven by insurance coverage and pricing strategies.
- The patent cliff for some large biologics scheduled between 2023 and 2027, creating upward pressure on biosimilar market penetration.
Regulatory Environment
- The FDA's pathway for biosimilar approval requires demonstrating similarity in safety, purity, and potency.
- CMS and private insurers incentivize biosimilar adoption through formulary preferences, affecting pricing and market penetration.
Price Trends and Projections
Current Pricing
- The average wholesale price (AWP) for biologics varies by product but ranges from USD 10,000 to USD 50,000 per treatment cycle.
- Biosimilars typically enter the market at 20-30% below the originator's price, with subsequent discounts leading to further reductions.
Price Drivers
- Patent expiration of originator biologics prompts price erosion.
- Competition among biosimilars drives prices down; the first biosimilar launches typically see a 15-25% price reduction relative to the reference biologic.
- Payer incentives favor biosimilar use, further pressuring prices.
Future Price Expectations
| Year |
Estimated Price Range (USD) per Treatment Cycle) |
Notes |
| 2023 |
50-70% of originator price |
Entry phase with nascent biosimilar competition |
| 2025 |
40-60% of originator price |
Increased biosimilar availability pressures prices |
| 2030 |
30-50% of originator price |
Market saturation and increased biosimilar innovation |
- The price reduction trajectory will depend on approval timelines, market acceptance, and payer policies, with some biosimilars already pricing at a 25% discount [2].
Market Growth Factors
- Increasing prevalence of autoimmune diseases and cancer.
- Expiration of patents for blockbuster biologics.
- Policy initiatives encouraging biosimilar adoption.
- Rising healthcare expenditure and emphasis on cost-effective treatments.
Risks and Limitations
- Slower-than-anticipated biosimilar adoption due to brand loyalty or prescriber hesitancy.
- Regulatory delays or additional efficacy/safety data requirements.
- Potential patent litigations or legal barriers.
Key Takeaways
- The product associated with NDC 42806-0133 operates within a rapidly expanding biologics market.
- Biosimilar competition is likely to become more intense, leading to price reductions.
- Prices are projected to decline by 50-70% relative to originator biologic prices over the next decade.
- Market growth will be driven by biological development, patent expirations, and payer incentives.
- Pricing will vary based on regional approvals, market access, and formulary decisions.
FAQs
1. How quickly do biosimilar prices typically decrease after launch?
Biosimilars often see a 15-25% price reduction within the first year, with further reductions as market penetration increases.
2. What factors influence biosimilar market share?
Regulatory approval timelines, physician acceptance, payer coverage policies, and price discounts impact biosimilar uptake.
3. When are major biologic patents expiring?
Patents for several top biologics, such as Humira and Enbrel, expire between 2023 and 2027, opening market opportunities.
4. How does FDA regulation impact biosimilar pricing?
Stringent approval requirements can delay biosimilar entry but generally lead to competitive pricing once approved.
5. What regions show the most significant biosimilar growth potential?
North America and Europe lead, with emerging markets in Asia and Latin America expected to see increased adoption over the next decade.
References
[1] Grand View Research. (2022). Biologics Market Size, Share & Trends Analysis.
[2] IQVIA. (2022). Biosimilar Market Dynamics and Pricing Trends.
